Valneva and Dynavax Collaborate to Develop COVID-19 Vaccine

Valneva and Dynavax Technologies have teamed up to develop a COVID-19 vaccine.

The partnership will combine Valneva’s vaccine candidate VLA2001 with Dynavax’s CpG 1018 adjuvant.

Valneva previously used the inactivated virus technology for an encephalitis vaccine, and Dynavax used the adjuvant in its FDA-approved hepatitis B vaccine.